Regenxbio (RGNX) EBIT (2014 - 2025)

Regenxbio's EBIT history runs 12 years deep, the most recent figure standing at -$57.6 million for Q4 2025.

• In Q4 2025, EBIT fell 12.2% year-over-year to -$57.6 million; the TTM figure through Dec 2025 stood at -$161.2 million (up 30.92% YoY), while the FY2025 annual figure was -$161.2 million, up 30.92% from the prior year.
• EBIT was -$57.6 million for Q4 2025 at Regenxbio, down from -$52.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $313.6 million in Q4 2021 to a low of -$73.1 million in Q2 2023.
• Historically, EBIT has averaged -$38.3 million across 5 years, with a median of -$59.9 million in 2022.
• Biggest YoY gain for EBIT was 684.51% in 2021; the steepest drop was 511.07% in 2021.
• A 5-year view of EBIT shows it stood at $313.6 million in 2021, then sank by 118.42% to -$57.8 million in 2022, then decreased by 10.61% to -$63.9 million in 2023, then climbed by 19.62% to -$51.4 million in 2024, then retreated by 12.2% to -$57.6 million in 2025.
• The last three EBIT figures came in at -$57.6 million (Q4 2025), -$52.4 million (Q3 2025), and -$63.3 million (Q2 2025), per Business Quant data.